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Abstract
Indolylarylsulfones are a potent class of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase
inhibitors. In this review, the structure activity relationship (SAR) studies to improve the profile of sulfone L-737,126
discovered by Merck AG have been analysed with focus on introduction of the 30,50-dimethyl groups at the 3-phenyl-
sulfonyl moiety, the 2-hydroxyethyl tail at the indole-2-carboxamide nitrogen, coupling of the carboxamide nitrogen with
one or two glycinamide and alaninamide units, a fluorine atom at position 4 of the indole ring and correlation between
configuration of the asymmetric centre and linker length. IAS derivatives look like promising drug candidates for the
treatment of AIDS and related infections in combination with other antiretroviral agents.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) is the
causative agent of HIV infection and acquired immu-
nodeficiency syndrome (AIDS). HIV remains a major
global public health issue, having claimed more than
35 million lives so far. AIDS and HIV-related infection
caused some 1.1 million deaths in 2015 with more than
two million HIV newly infected people.1 Current com-
bination antiretroviral therapies (cART) combine
drugs targeting different steps of the HIV life cycle:
combination of three or four antiretroviral drugs has
proven to inhibit effectively the infection in HIV-1-
infected people adhering to a cART regimen.1 One
cART pill a day remarkably reduces the risk of acquir-
ing the infection in pre- and post-exposure prophylaxis
to HIV uninfected people.2 Thus far, there are no safe
and effective vaccines available for HIV. A National
Institutes of Health funded study suggested that HIV
preventive vaccination could reduce the number of
HIV-infected people by 36% globally over a period
of 15 years.3
The approved anti-HIV-1 drugs can be viewed
as falling in five main classes: nucleoside reverse tran-
scriptase inhibitors (NRTIs) and nucleotide reverse
transcriptase inhibitors, non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), protease inhibitors
which prevent the maturation step, viral entry inhibi-
tors (fusion inhibitors and co-receptor antagonists) and
integration inhibitors.4–8 These antiretroviral drugs are
taken singly or combined into multidrug pills.9 The
cART regimens have proven to be effective inhibitors
of the HIV replication and prevent the breakthrough of
the infection in early stages of the disease. After start-
ing treatment with cART, the levels of plasma viraemia
fall below the limit of detection within 24 weeks and
remain for at least six months in most treated
patients.10,11 Despite its great initial effectiveness,
long-term cART treatments cause the development of
Department of Drug Chemistry and Technologies, Sapienza University of
Rome, Laboratory affiliated to Istituto Pasteur Italia – Fondazione Cenci
Bolognetti, Roma, Italy
Corresponding author:
Romano Silvestri, Department of Drug Chemistry and Technologies,
Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur
Italia – Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, Roma I-
00185, Italy.
Email: romano.silvestri@uniroma1.it
Antiviral Chemistry and Chemotherapy
2018, Vol. 26: 1–19
! The Author(s) 2018
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2040206617753443
journals.sagepub.com/home/avc
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction
and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages
(https://us.sagepub.com/en-us/nam/open-access-at-sage).
drug resistance12 and cross resistance among com-
pounds of the same class,13–15 toxicological problem
and adverse side reaction, with associated compliance
failure to the prescribed cART regimens.16 There is still
a need of new antiretroviral drugs with improved resis-
tance profiles and better tolerability.
Reverse transcriptase (RT) is a heterodimeric
enzyme which is composed of two subunits, p66 and
p51.17,18 The RT catalyses the transformation of
the RNA retroviral genome into proviral DNA19 The
catalytic core of the RT is placed in the p66 subunit
and resembles a right hand with fingers, palm, thumb
and connection subdomains. The p51 subunit does not
exhibit any catalytic activity and shows structural
capacity only.20,21 The NNRTIs behave as non-
competitive allosteric inhibitors at the non-nucleoside
binding site (NNBS) located a 10 A˚ distance from the
catalytic site in the p66 palm subdomain.22,23
On 21 June 1996, the U.S. Food and Drug
Administration (FDA) approved the first HIV-1
NNRTI, nevirapine ([1], NVP) (Viramune, Boehringer
Ingelheim), for use in combination with NRTIs in HIV-
1-infected adults. On 4 April 1997, delavirdine mesylate
([2], DLV) (Rescriptor, Pharmacia & Upjohn) and on 17
September 1998 efavirenz ([3], EFV) (Sustiva, DuPont)
were approved for the treatment of HIV-1 infection.
Etravirine ([4], ETR) (TMC-125, Intelence, Tibotec)
and rilpivirine ([5], RPV) (Edurant, Tibotec) were
approved by the FDA on 18 January 2008 and
20 May 2011, respectively, for treatment in drug
combination of HIV-1-infected people for whom
NNRTI-based therapies have failed (Chart 1).
First sulfone HIV-1 NNRTIs
In 1993, McMahon et al.24 at the National Cancer
Institute (NCI) of Bethesda started a drug-screening
programme to identify new synthetic compounds and
natural products with anti-HIV-1 activity. This study
led to the selection of 2-nitrophenyl phenyl sulfone ([6],
NPPS) (Chart 2), a diarylsulfone which showed appre-
ciable anti-HIV-1 activity at micromolar concentra-
tion. Studies on diarylsulfone congeners led to the
discovery of potent classes, such as 2-carboxamido-3-
arylsulfonylthiophene [7],25 2-amino-6-arylsulfonylben-
zonitrile [8]26 and diarylsulfone27 derivatives.
At the time of the diarylsulfone project at the NCI,
new pyrryl aryl sulfones (PASs) structurally related to
NPPS, for example 2-nitro-PAS [9], were synthesized.
First-generation PASs were characterized by a nitro
group at position 2 of the benzene ring and an ethox-
ycarbonyl group at position 2 of the pyrrole nucleus.28
An important progress in PAS development was
achieved by replacing the 2-nitrobenzene group with
a 4-chloroanilino moiety to obtain 2-amino-PASs, for
example [10], with potent antiviral activity at micromo-
lar concentrations.29–32 The 4-chloroaniline was also a
key pharmacophore for the antiretroviral activity of
pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs, for
example [11]).32–34 PBTD NNRTIs, structurally related
Chart 1. HIV-1 NNRTIs in clinical practice.
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to NVP, were obtained by intramolecular cyclization
of PASs.33
Indolylarylsulfone (IAS) HIV-1 NNRTIs
In 1993, Merck Research Laboratories reported
the discovery of 5-chloro-3-(benzenesulfonyl)indole-2-
carboxyamide (L-737,126; [12]) that showed potent and
selective inhibition of HIV-1 WTIIIB strain with EC50
of 1 nM.35–37 Carboxamide [12] proved to be highly
potent as inhibitor of the HIV-1 WT strain (EC50¼
1 nM).38 Introduction of a methyl group at position
20, 30 or 40 of the 3-phenylsulfonyl ring led to IAS
derivatives less cytotoxic than [12]. IAS derivatives
bearing the 20,40- or 30,50-dimethyl [13] substitution pat-
tern at the 3-phenylsulfonyl group were more cytotoxic
than the monomethyl derivatives. Most importantly,
the two methyl groups at positions 30 and 50 of the
3-phenylsulfonyl moiety proved to be a key structural
requirement for an effective inhibition of the HIV-1
mutant strains38 (Chart 3). IAS derivative [13] exhib-
ited potent activity against the HIV-1 WT (EC50¼
4 nM) and the HIV-1 mutant strains Y181C (EC50¼
30 nM), K103N-Y181C (EC50¼ 650 nM) in MT-4 cells
(MTT method) and EFVR (EC90¼ 80 nM) in 8166 cell
(p24 method) (EFVR: EFV-resistant HIV-1 strain car-
rying K103R, V179D and P225H mutations; EFV
EC90¼ 1800 nM). These studies highlighted the role
of the 30,50-dimethyls against the drug-resistant HIV-1
mutant strains. In summary, compound [13] was com-
parable with [12] and EFV against HIV-1 WT and
Y181C mutant, but it was more potent than [12]
against the HIV-1 K103N-Y181C mutant, and superior
to [12] and EFV against the EFVR mutant strain.
Hydroxyethyl derivatives
Efforts to improve water solubility and bioavailability
of [12] led Merck to synthesize a series of bioisosteres
by replacing the 2-carboxamide with a nitrogen-
containing heterocycle.39 Interestingly, among these
new compounds 3-(benzenesulfonyl)-5-chloro-2-(5-
methylimidazol-2-yl)indole [14] was found to be
11-fold superior to [12] against the HIV-1 K103N
mutant strain. Molecular modelling studies were per-
formed to gain insight of the binding mode of [12] into
the NNBS of 14 RTs. A 3D quantitative structure
activity relationship (SAR) model was obtained using
a training set of 70 IAS derivatives.40 The structure of
the diarylsulfone 739W9424 in complex with the HIV-1
RT (PDB code 1jlq) was used to model the training
set.27 These findings prompted the synthesis of IAS
derivatives bearing a 2-hydroxyethyl tail at the
indole-2-carboxamide or indole-2-carboxydrazide
nitrogen.41,42 Carboxamide [15] and carboxhydrazide
[16] were the most potent inhibitors of the HIV-1
Chart 2. Diarylsulfones [6]–[8], pyrrylarylsulfone [9] and [10], and pyrrolo[1,2-b][1,2,5]benzothiadiazepine [11].
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WTIIIB strain (EC50¼ 1 nM) in MT-4 cells (MTT
method). IAS [15] was superior to [12] against the
HIV-1 Y181C and K103N-Y181C mutants and was
more potent than [12] and EFV against the EFVR
mutant strain. IASs [15] and [16] were as potent as
EFV against the HIV-1 WT RT, superior to EFV
against the HIV-1 K103N mutant, but slightly inferior
as inhibitor of the HIV-1 KY181I mutation (i.e. com-
parable with the Y181C in terms of drug resistance).
N0-carbohydrazide derivatives
The training set of the 3D quantitative SAR model40
was enlarged from 70 to 101 compounds to improve the
predictive capability.43 Docking simulations and 3D
quantitative SAR models led to design new potent car-
bohydrazide derivatives. IASs [17] and [18] showed
strong inhibition of the HIV-1 WTIIIB strain in MT-4
cells with EC50 of 3 and 0.7 nM, respectively, and high
selectivity indexes. Compound [17] inhibited the HIV-1
K103N-Y181C double mutant with EC50¼ 900 nM.
Compounds [17] and [18] were evaluated against
the primary isolates HIV-1 WTIIB, HIV-112 and
HIV-AB1 carrying K103N–V108I–M184V and
L100I–V108I mutations, respectively, from two HIV-
1-Ab seropositive patients who developed treatment
failure after an initial response to the cART therapy.
In lymphocytes compound [18] inhibited the primary
isolates with subnano- (IIIB) or low nanomolar (112,
AB1) EC50 values; in macrophages, [17] inhibited the
HIV-1 IIIBBa-L with EC50 of 2 nM and showed selec-
tivity index >10.000.
IAS containing peptide units
Efforts to improve the interaction of IAS NNRTIs
with the NNBS of the HIV-1 RT prompted the
design of IAS derivatives bearing 1–3 glycine/alanine
unit(s) at the 2-carboxamide nitrogen. The chemical
manipulations included, for example, transposition of
N-acetylamino to 2-acetamido, or replacement of semi-
carbazide with glycine carbohydrazide (Chart 4).44 IAS
derivatives bearing the glycine [20], alanine [21] or gly-
cine–glycine [22] unit strongly inhibited the HIV-1
WTIIIB strain with EC50s of 3, 6 and 0.7 nM, respec-
tively. As inhibitors of the HIV-1 Y181C mutant strain,
IASs [21] and [22] showed EC50 of 10 and 5 nM, respec-
tively. IASs [20] and [22] inhibited the HIV-1 K103N–
Y181C double mutant with EC50s of 800 and 700 nM.
IASs [20]–[22] inhibited the EFV-resistant HIV-1
K103R–V179D–P225H strain with EC50s of 100, 40
and 100 nM, respectively38 (Chart 4).
These results prompted the synthesis of new IAS
derivatives bearing natural and unnatural amino
acid units at the indole-2-carboxamide, for example
[23] and [24].45 As inhibitors of the HIV-1 WTIIIB
strain in CEM cells the new IASs yielded nanomolar
EC50 concentrations ([23]: EC50¼ 1.4 nM; [24]:
EC50¼ 2.3 nM) and were comparable with EFV. The
new compounds inhibited the Coxsackie B4 viruses
with EC50s of 2–9 mm. These agents showed the
Chart 3. IAS carboxamides [12], [13] and [15]; carboxamide bioisostere [14] and carbohydrazides [16]–[18].
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potential as new drugs to treat both the HIV-1 and
Coxsackie B4 infection.45
IASs containing two halogen atoms
The HIV-1 K103N mutant strain is the most frequent
mutation in >90% EFV-treated patients whose viral
load rebounded after an initial response to the drug.
The K103 mutation is frequently followed by the
HIV-1 K103N–V108N and K103N–P225H double
mutations.46 Moreover, drug expedited clearance may
result as a consequence of upregulation of P450 liver
isoenzyme CYP3A4.47 Efforts to improve the activity
of EFV48 against the drug-resistant mutants led
DuPont Pharmaceuticals to synthesize quinazolinone
analogues with two halogen atoms49,50 (Chart 5).
Compounds with the halogen atoms at positions 5
and 6 of the quinazolinone ring, for example [25] and
[26], were superior to the corresponding 5- and
6-mono-halogenated counterparts, partly due to the
weaker binding with the plasma proteins.51
New IAS derivatives bearing two halogen atoms at
positions 4–7 of the indole ring were synthesized based
on these findings.52 Introduction of chlorine and fluo-
rine atoms at positions 4 and 5 of the indole provided
highly potent HIV-1 NNRTIs. The di-halo IASs [27]
and [28] exhibited potent inhibition of HIV-1 WTIIIB
strain in MT-4 cells with EC50s of 1.0 and 0.5 nM,
respectively. As inhibitor of the HIV-1 Y181C and
K103N–Y181C mutant strains, [28] was comparable
with EFV. Compounds [27] and [28] effectively inhib-
ited the primary isolates 112 and the AB1 strains in
lymphocytes and the HIV-1 WTIIIB Ba-L strain in mac-
rophages (p24 method).
Di-halo-IASs showed selectivity for the enzyme–
substrate complex because of a different dissociation
rate of the drug from the enzymatic form along the
reaction pathway.53 By comparing the HIV-1 WT RT
Chart 5. Di-halo IASs [27] and [28] correlated to quinazolinones [25] and [26].
Chart 4. IAS acetylhydrazide [19] and IASs containing peptide units [20]–[24].
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and drug-resistant K103N-, L100I- and Y181I-mutated
RTs, IAS derivatives were characterized by highly
dynamic interaction with the viral RT.53,54 A greater
flexibility of IAS [28] to form stable interactions with
the amino acid residues of the NNBS of the RT may
correlate with the potent anti-HIV-1 activity.55
IASs with a third ring
HIV-1 NNRTIs containing three aromatic rings, for
example diaryltriazine (Janssen, NJ, USA),56 dipyrido-
diazepinone (Boehringer Ingelheim, CT, USA)57,58 and
pyrrolidin-1-ylsulfone (Merck, PA, USA)59 derivatives,
showed potent and broad spectrum anti-HIV-1 activi-
ty. Previous docking studies of IAS derivatives contain-
ing a short peptide unit44,45 highlighted that a tail at the
2-carboxamide nitrogen could form effective binding
interactions inside the NNBS of the RT surrounded
by the R172, I180, V179 and E138:B, and T139:B
amino acid residues. These computational studies
served as basis for the design of new IAS derivatives
characterized by the presence of a pyrrolidine/piperi-
dine/morpholine heterocyclic ring linked to the carbox-
amide nitrogen through a short 1–2 carbon spacer, for
example [29]–[32] (Chart 6).60 The new IAS bearing the
third nucleus showed potent inhibition of the HIV-1
WTIIIB strain in CEM cells with EC50 values at nano-
molar concentrations ([29]: EC50¼ 3.3 nM; [30]:
EC50¼ 1.3 nM; [31]: EC50¼ 1.9 nM; [32]:
EC50¼ 6.5 nM). As inhibitors of the HIV-1 L100I
and K103N mutant strains, [31] (EC50¼ 8.0 and
11 nM) and [32] (EC50¼ 11 and 15 nM) were superior
to EFV (EC50¼ 22 and 130 nM). Dissociation rates
showed that compounds [29] and [30] formed stronger
binding interactions with the L100I- and K103N-
mutated enzymes than the WT enzyme.61 IAS deriva-
tives [29], [31] and [32] inhibited the HIV-1 clade A in
peripheral blood mononuclear cells (PBMCs) with
EC50 values of 0.1, 0.1 and 2.1 nM, respectively.
Benzyl derivative [33] showed appreciable inhibition
of the HIV-1 WTIIIB strain in CEM cells and the HIV-1
mutant strains in MT-4 cells. These findings prompted
the synthesis of new IAS derivatives containing nitro-
gen heterocycles at the 2-carboxamide nitrogen.62
Among them, compound [34] showed consistent inhi-
bition of the HIV-1 WTNL4-3 strain (EC50¼ 2.0 nM) in
MT-4 cells, the HIV-1 K103N (EC50¼ 8.8 nM), Y181C
(EC50¼ 2.2 nM) and Y188L (EC50¼ 22 nM) mutant
strains and the HIV-1 IRLL98 multidrug-resistant
strain (EC50¼ 1 nM) containing the K101Q, Y181C
and G190A mutations conferring resistance to NVP,
DLV and EFV.63 Compound [34] was more active
against the IRLL98 mutant strain than the WT
NL4-3 strain, and it proved to be a potent inhibitor
of HIV-1 clades A, B, C, D, A/E, F and G in PBMCs
in the higher picomolar range, except clade G.
Compound [34] inhibited the HIV-1 K103N RT, the
major mutation emerging in EFV-treated patients,46
with EC50 of 45 nM, and exhibited EC50 of 11 nM
against the HIV-1 L100I RT. These new IASs shared
a typical feature of ETR, a state-of-art HIV-1 NNRTI,
that is the presence of a pendant (third) aromatic ring.55
Chart 6. IASs [29]–[34] containing a third cyclic ring.
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These results underline the potential of IAS [34] as a new
agent for the treatment of EFV-treated patients who
show the L100I and K103N mutations.
Focus on chirality of IASs
Chirality considerably affects the pharmacological pro-
file of the drugs due to the high specific interaction of the
ligand to the recognition site. Accordingly, the enantio-
selectivity plays an important role for the binding of
antiviral agents to HIV-1 RT.64 New IAS HIV-1
NNRTIs were synthesized to evaluate unexplored sub-
stitutions of the benzyl/phenylethyl group linked at the
indole-2-carboxamide.65 In recent studies, the enantiom-
ers of IASs bearing chiral centres demonstrated signifi-
cant differences in terms of antiretroviral activity.
Several IAS derivatives were superior to NVP and
EFV against the HIV-1 NL4-3 WT strain and inhibited
the HIV-1 K103N mutant strain at nanomolar concen-
tration. Some derivatives were superior to EFV against
the HIV-1 Y181C and L100I mutant strains. The race-
mate (R,S)-[35] was separated into the enantiomers
(R)-[35] and (S)-[35] by HPLC on the cellulose derived
coated Chiralcel OD chiral stationary phase (CSP) using
the binary mixture n-hexane–ethanol 1:1 as a mobile
phase at both analytical and semipreparative level.
Assignment of the absolute configuration of (R)-[35]
and (S)-[35] was achieved by (i) synthesis of the enan-
tiomer (S)-[35] starting from the amine of known ste-
reochemistry (S)-()-a-methylbenzylamine, and (ii)
comparison of the enantiomeric peaks of (R)-[35]
and (S)-[35] obtained from the enantioseparation
under the same enantioselective HPLC conditions.
Against the NL4-3 HIV-1 strain, the enantiomers (R)-
[35] and (S)-[35] showed small differences of activity. In
contrast, (R)-[35] was found to be significantly more
potent than (S)-[35] against the HIV-1 mutant strains
((R)-[35] EC50, (S)/(R) ratio: K103N (4.3 nM, 30-
fold), Y181C (86 nM, 40-fold), Y188L (193 nM,
>189-fold) and K103N-Y181C (1670 nM, >22-fold))
(Chart 7).
Docking studies of (R)-[35] and (S)-[35] in the
HIV-1 WT RT gave similar results. However, into
the HIV-1 K103N-mutated RT the methyl group of
the (R)-[35] pointed towards the entrance channel
of the NNRTI NNBS, while the corresponding group
of the (S)-[35] pointed towards the bottom of the cleft,
leaving the binding pocket more exposed to the aque-
ous environment. The difference in the observed
biological activity of (R)-[35] and (S)-[35] could be
due to a different binding kinetics rather than affini-
ty.66 (R)-[35] was able to seal the binding pocket, while
(S)-[35] left the site accessible to water with a conse-
quent negative impact on the binding kinetic of this
inhibitor.
Further step of this research project was the synthe-
sis of IAS derivatives carrying a heterocyclic tail at the
indole-2-carboxamide nitrogen.67 Several new IASs
inhibited the HIV-1 WT and mutant strains in MT-4
cells with EC50 values less than 1.0 nM. Replacement of
the phenyl group of [35] with a pyridinyl ring to obtain
[36] resulted in a general improvement of antiviral
Chart 7. Chiral IASs [35]–[39].
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activity. Racemate [36] was found to be three-fold
more potent than [35] as inhibitor of the NL4-3 WT
strain (EC50¼ 0.2 nM,). Against the K103N
(EC50¼ 9.4 nM), Y181C (EC50¼ 87 nM) and
K103N-Y181C (EC50¼ 1111 nM) mutant strains, IAS
[36] was, respectively, three, eight and three times supe-
rior to [35].
The racemate (R,S)-[36] was separated into the
enantiomers (R)-[36] and (S)-[36] by enantioselective
HPLC. The CD spectra of enantiomers (R)-[36] and
(S)-[36] were compared with those of (R)-[35] and
(S)-[35].65 Similar to the enantiomers of [35], (R)-
[36] and (S)-[36] (EC50¼ 0.2 nM) were equipotent
against the HIV-1 WTNL4-3 strain; on the contrary,
(R)-[36] showed higher inhibition than (S)-[36] of
the HIV-1 mutant strains ((R)-[36] EC50, (S)/(R)
ratio: K103N (0.2 nM, 22-fold), Y181C (2.1 nM, 61-
fold) and K103N-Y181C (150 nM, 27-fold)) in the cel-
lular assay. Compound (R)-[36] was superior to NVP,
EFV and AZT reference drugs, except AZT, against
the K103N–Y181C mutant strain. In addition, com-
pounds (S)-[36] and (R)-[36] were evaluated against
various HIV-1 group M clinical isolates in PBMC.
The antiviral activity was potent and consistent and
varied only between 0.7 and 5.2 nM when evaluated
against all different virus isolates. Compound (R)-
[36] showed excellent plasma and metabolic stability
and did not behave as a prodrug. It showed good mem-
brane permeability and low water solubility.67 Shifting
the 4-nitrogen of the pyridine to either position 3 or 2
resulted in a decreased anti-HIV-1 activity against the
mutant strains.
From docking simulations in the HIV-1 WT RT, the
PLANTS proposed binding mode of (R,S)-[36] was
consistent with the previously reported binding poses
for the IAS family41–45,52,55,60,62,65 featuring these phar-
macophoric interactions: (i) the indole NH established
a H-bond with the K101 carbonyl oxygen; (ii) the chlo-
rine atom fitted into a hydrophobic cavity surrounded
by V106 and L234; (iii) the 30,50-dimethylphenyl moiety
laid in the aromatic cleft formed by the side chains of
Y181, Y188 and W229 residues establishing a network
of hydrophobic interactions; (iv) the pyridyl moiety
formed hydrophobic interactions with the side chains
of V179 and E138:B (Figure 1).
The (R)-[36] and (S)-[36] enantiomers showed
some significant differences in their binding modes:
the methyl group of (R)-[36] pointed towards the
cleft created by the K103N mutation, sealing the bind-
ing pocket and reducing the solvent-accessible surface,
Figure 1. Sketch of amino acid residues within 5 A˚ of IAS (R,S)-[36] bounded in the NNBS of the HIV-1 WT RT.
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the corresponding group of (S)-[36] left the pocket
more exposed to solvent, in agreement with the previ-
ously reported mechanism of resistance to the HIV-1
K103N mutation based on a binding kinetic effect.66,68
Molecular dynamics simulations showed that trajecto-
ry analyses of both K103N RT/((R)-[36] and K103N
RT/(S)-[36] complexes were stable during the whole
simulation time. Solvent-accessible surface area69 per-
formed on the entire binding site of the receptor in
complex with (S)-[36] (235.64 A˚2) was greater than
the corresponding one for the (R)-[36], (210.20 A˚2).
(S)-[36] showed a number of water molecules sur-
rounding the methyl cleft, 3.5 times greater than the
number of solvent molecules observed for the (R)
Figure 2. Sketch the 1-(pyridin-4-yl)ethyl group of derivatives (R)-[36] and (S)-[36] into the NNBS of the K103N RT. The image
shows a different shape and position of the methyl group.
Chart 8. Indolylsulfonamides [40]–[43] and API [44] and [45].
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enantiomer. These results were taken into account to
explain the different biological activity observed
between (R)-[36] and (S)-[36] enantiomers (Figure 2).
A new series of chiral IASs showed potent inhibition
of the HIV-1 WT NL4-3 strain and of the HIV-1
K103N, Y181C, Y188L and K103N-Y181C HIV-1
mutant strains.70 Six racemic mixtures were separated
at the semipreparative level by enantioselective HPLC
into their pure enantiomers. The (R)-enantiomers of
IAS derivatives bearing the chiral a-methylbenzyl were
superior to the (S)-counterparts. IAS (R)-[37] inhib-
ited the HIV-1 WT strain with EC50 of 0.7 nM, and
K103N (EC50¼ 0.7 nM), Y181C (EC50¼ 0.7 nM),
Y188L (EC50¼ 165 nM) and K103N–Y181C
(EC50¼ 2486 nM) in the cellular assay. In previous
studies, the antiretroviral activity of IAS [21] appeared
only weakly affected by the chirality of the alanine
unit.45 On the contrary, coupling of alanine with
pyridin-4-ylmethanamine provided IAS derivatives
with marked stereospecific activity: (S)-[38] was supe-
rior to the corresponding (R)-enantiomer, and
(S,R)-[39] and (S,S)-[39] were superior to the corre-
sponding (R,S)-[39] and (R,R)-[39] enantiomers. IASs
(R)-[38] and (S)-[38] were equally active against the
HIV-1 WTNL4-3 with EC50¼ 0.7 nM. Otherwise,
(S)-[38] was really more potent than (R)-[38] against
Scheme 1. Synthesis of IASs [13], [15] and [16].
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the HIV-1 mutant strains (EC50, (S)/(R) ratio)
K103N (0.7 nM, 162-fold), Y181C (0.7 nM, 258-
fold), Y188L (666 nM, >35-fold) and K103N–Y181C
(857 nM, eight-fold) in MT-4 cells. The cellular data
correlated with the enzymatic results. The diastereo-
meric mixture [39] was separated into the four stereo-
isomers (R,S)-[39], (S,R)-[39], (R,R)-[39] and
(S,S)-[39]. IASs (S,R)-[39] and (R,S)-[39] showed
marked differences against the HIV strains (EC50,
(S)/(R) ratio) WTNL4-3 (0.6 nM, three-fold), K103N
(0.6 nM, 340-fold), Y181C (0.6 nM, 1113-fold), Y188L
(742 nM, 38-fold) and K103N–Y181C (1261 nM,
25-fold). The biological results highlighted a
correlation between configuration of the asymmetric
centre and linker length: The (R)-enantiomers were
superior to the (S)-counterparts when associated to a
short linker unit, and the (S)-enantiomers were more
potent than the (R)-enantiomers in the presence of a
long linker.
Despite the significant increase of life expectancy in
HIV-infected people,71 cART treatments cause neuro-
logical problems to nearly half of HIV cases.72 The
neurocognitive damage often accelerates during
cART treatment73 and continues even after the periph-
eral viral infection has ceased.74 Compound (R,S)-[38]
protected hippocampal neuronal cells from the
Scheme 2. Synthesis of IASs [20]–[22].
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excitotoxic insult, while EFV did not contrast the neu-
rotoxic effect of glutamate. The new IASs showed
improved resistance profile against the mutant HIV-1
strains and reduced neurotoxic effects.
Indole-3-sulfonamides, Merck & Co., Inc
Fifteen years after the discovery of compound [12],35
Merck & Co., Inc. reported the synthesis of a series of
indolylsulfonamides bearing a linear or cyclic alkyl-
amine linked at the sulfone group at position 3 of the
indole.59 Preliminary docking studies suggested that a
3-alkylsulfonamide and a halogen atom at position 5 of
the indole could increase the activity against the HIV-1
Y181C mutant strain. Both secondary and tertiary sul-
fonamides inhibited the HIV-1 RT with IC50 values at
nanomolar concentration. In HIV-1 WT-infected cells,
only pyrrolidine [40], [41] and piperidine tertiary sulfo-
namides showed inhibitory concentrations (Spread
CIC95) comparable to the enzymatic assay. X-ray
co-crystal structure of [40] bound to HIV-1 WT RT
revealed that it assumed a ‘butterfly-like’ orientation,
similarly to [12] and other NNRTIs.55 However, [40]
and [41] showed weak inhibition of the HIV-1 K103N
Scheme 3. Synthesis of ethyl 5-chloro-4-fluoro-1H-indole-2-carboxylate [62].
Scheme 4. Synthesis of ethyl 5-chloro-4-fluoro-1H-indole-2-carboxylate [56].
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and Y181C mutant strains. Efforts to improve the
activity against the mutant strains led to modification
of the 2-carboxmide function, as previously reported
by Young et al.,39 with introduction of a benzyl
group at the carboxamide nitrogen (e.g. [42]), or
replacement of the carboxamide with an imidazole
ring (e.g. [43]). Compounds [42] and [43] showed inhi-
bition of the HIV-1 K103N and Y181C mutants com-
parable to the WT in both enzymatic and cellular
assays (Chart 8).
Arylphosphoindoles, Idenix Laboratories
Idenix Laboratories synthesized bioisosteres of the IAS
derivatives by replacing the 3-sulfonyl bridging group
with a phosphinic acid methyl ester one.75
Arylphosphoindole (API) derivative [44] inhibited the
HIV-1 WT and the K103N, Y181C mutant strains at
low nanomolar concentration. The racemic mixture
[44] was separated into the corresponding enantiomers
by supercritical fluid chromatography. In MT-4-
infected cells, the enantiomer (R)-[44] inhibited the
HIV-1 WT with EC50 of 0.1 nM and the HIV-1
mutant strains K103N, Y181C and K103N-Y81C with
EC50 values of 1.2, 3.6 and 137.4 nM, respectively. The
stereochemistry of (R)-[44] was assigned on the basis of
binding energy calculation (23 kcal/mol) and was con-
firmed by X-ray crystallography diffraction.
Idenix introduced the typical Z-cyanovinyl arm of
RPV at position 30 of the 3-phenyl phosphinic group
to obtain HIV-1 NNRTIs with broad spectrum of
activity against the drug-resistant mutant strains.
Scheme 5. Synthesis of IASs [29], (R)-[35] and (S,R)-[39].
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The enantiomer (R)-[45] (IDX 899) showed effective
inhibition of the HIV-1 WT and of the HIV-1 mutant
strains resistant to other NNRTIs, reduced HIV-1
RNA levels and exhibited barrier to resistance superior
to EFV. (R)-[45] was selected as highly potent second-
generation NNRTI drug candidate and was evaluated
in a phase II clinical trial. In February 2009 it was
licensed to GlaxoSmithKline and its name was changed
to fosdevirine/GSK2248761.76 In phase I clinical trials
increased CD4þ cell counts in treatment-naı¨ve patients
infected with HIV-177,78 (Chart 8).
Synthetic aspects
Compound [13] was synthesized starting from
acid [46a] which transformed into the 3-arylthio inter-
mediate [47] by Atkinson reaction79 with an appropri-
ate arylthiodisulfide in the presence of sodium hydride
and then transformed in the corresponding methyl ester
[48] with trimethylsilyl diazomethane. Alternatively,
[48] was obtained from ester [46b] and N-(3,5-dimethyl-
phenylthio)succinimide in the presence of boron tri-
fluoride diethyl etherate. Compound [48] was oxidized
to sulfone [49] with 3-chloroperoxybenzoic acid.
Finally, [49] was heated with ammonium hydroxide in
closed vessel to give [13]. Heating of [49] in
ethanolamine or 2-hydrazinoethanol furnished IAS
[15] or [16], respectively (Scheme 1).
IAS derivatives [20]–[22] were synthesized starting
from ester [49]. LiOH hydrolysis of [49] at room tem-
perature yielded the carboxylic acid [50]. The acid was
treated with glycine or alanine in the presence of BOP
reagent (benzotriazol-l-yl-oxy-tris-(dimethylamino)
phosphonium hexafluorophosphate) and triethylamine
as coupling reagents to provide esters [51] or [52]. These
compounds were transformed into IASs [20] or [21]
with concentrated ammonium hydroxide in ethanol at
60 C. Glycine ester [51] underwent alkaline hydrolysis
with LiOH to give acid [53]. Elongation of the chain
was performed by coupling [53] with a glycine unit in
the presence of BOP reagent and triethylamine. Finally,
ester [54] was transformed into IAS [22] by heating at
60 C with ammonium hydroxide (Scheme 2).
Di-halo-IASs [27] and [28] were synthesized by fol-
lowing the above reported procedure starting from
an appropriate ethyl di-halo-1H-indole-2-carboxylate.
The required esters were prepared from the
corresponding phenylhydrazones80 by Fisher indole
synthesis in polyphosphoric acid at 100 C.81 The iso-
meric esters were separated with difficulty by column
chromatography after repeated passages providing
[62] in 5% yield.82 To improve yield, [62] was
synthesized starting from 3-fluoro-2-methylaniline
Scheme 6. Synthesis of indolylsulfonamides [40] and [43].
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[55]. The N-pivaloyl derivative [56] was treated with
N-chlorosuccinimide to give the 4-chloro derivative
[57]. After hydrolysis of [57] with hydrochloric acid,
the aniline [58] was oxidized to nitro [59] with
3-chloroperoxybenzoic acid. Treatment of the latter
compound with diethyl oxalate in the presence of
sodium ethoxide gave ethyl 3-(3-chloro-2-fluoro-6-nitro-
phenyl)-2-oxopropanoate [60]. Iron powder reduction of
[60] followed by intramolecular cyclization provided [62]
in six steps and 37% overall yield83 (Scheme 3).
Idenix Pharm. (MA, USA) synthesized [62] starting
from 4-chloro-3-fluoroaniline [63].84 C2 iodination of
BOC-protected [64] afforded [65]. After deprotection of
[65] with hydrochloric acid, the aniline [66] was reacted
with pyruvic acid in the presence of palladium(II)
acetate and 1,4-diazabicyclo[2.2.2]octane to afford
5-chloro-4-fluoro-indole-2-carboxylic acid [67].
Esterification of [61] to [62] was easily achieved by
treatment with 1,10-carbonyldiimidazolole and then
with methanol (Scheme 4).
Compound [29] was synthesized according to the
Mannich reaction by refluxing [13] in tert-butanol at
100 C with pyrrolidine in the presence of 37% form-
aldehyde or paraformaldehyde using a Dean–Stark
trap.60 Reaction of (S)-()-a-methylbenzylamine
with acid [50] in the presence of BOP reagent and
Scheme 7. Synthesis of API (R)-[45].
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triethylamine in DMF at room temperature furnished
the chiral IAS (R)-[35]. This compound was used as a
reference compound to compare the peaks of enan-
tiomers (R)-[35] and (S)-[35] obtained by enantiose-
paration of the racemate [35].65 Acid [68] was obtained
by LiOH hydrolysis of the racemic ester [52].
Treatment of [52] with the racemic a-methylbenzyl-
amine in the presence of BOP reagent and triethyl-
amine to furnish the diasteromeric compound [39].
HPLC separation of the enantiomers was performed
using a polysaccharide-based CSP Chiralpak IC and
n-hexane–ethanol–dichloromethane–DEA 40:15:45:0.3
as eluent70 (Scheme 5).
Ethyl 5-bromo-1H-indole-2-caboxylate [69] was pro-
tected with 4-toluensulfonyl chloride in the presence of
NaH to give [70] and converted to sulfonyl chloride [71]
with sulfuryl chloride. The sulfonyl chloride was
treated with pyrrolidine to afford [72]. Aminolysis of
the 2-ethoxycarbonyl group with ammonia underwent
concomitant deprotection of position 1 of the indole to
provide [40]. Deprotection of [72] with tris-(2-amino-
ethyl)aminomethyl polystyrene (PS-trisamine) gave
[73]. The ester was transformed to aldehyde [74] by a
two-step procedure with lithium aluminium hydride
and subsequent oxidation with manganese(IV) oxide.
The latter compound was cyclized to imidazole [43]
with acetaldehyde and ammonium hydroxide under
microwave irradiation (Scheme 6).
Compound (R)-[45] (IDX899)85 was synthesized
starting from an aryl halide or triflate [75] in the
presence of Mg or an alkyl Li and PCl3 to provide
dichlorophosphite [76]. Compound [76] was treated
with (þ)- or ()-menthylchloroformate [77] in pyridine
(Hewitt reaction)86 to give the mixture of diaster-
eoisomers [78] and [79] which were separated by
crystallization at low temperature in n-hexane.
Compound [78] was treated with ethyl 3-bromo-5-
chloro-1-phenylsulfonyl-1H-indole-2-carboxylate [80]
in the presence of tris(dibenzylideneacetone)
dipalladium(0)-chloroform adduct (Pd2(dba)3CHCl3)
and triethylamine to give [81]. Formation of [82]
from [80] and trimethyloxonium tetrafluoroborate
(Meerwein salt) and then trifluoroacetic acid under-
went with inversion of configuration. Finally, (R)-
[45] was obtained by reaction of [82] with ammonium
hydroxide, or, alternatively, by hydrolysis of the ester
with lithium hydroxide and subsequent treatment with
ammonia by displacement of the intermediate imidazo-
lide (Scheme 7).
Conclusions
IASs are a potent class of HIV-1 NNRTIs. SAR stud-
ies led to improve remarkably the profile of L-737,126
discovered by Merck AG. Introduction of the
30,50-dimethyl groups at the 3-phenylsulfonyl moiety
furnished IAS derivatives with potent and selective
activity against HIV-1 mutants carrying NNRTI resis-
tance mutations at positions 103 and 181 of the RT.
The presence of a 2-hydroxyethyl tail at the indole-2-
carboxamide nitrogen improved the activity against the
HIV-1 K103N–Y181C double mutant. Coupling of the
carboxamide nitrogen with one or two glycinamide and
alaninamide units moieties produced short peptides
with potent activity and selectivity against the HIV-1
WT and the mutant strains Y181C, K103N-Y181C and
EFVR carrying K103R, V179D and P225H mutations.
Introduction of a fluorine atom at position 4 of the
indole ring improved the antiviral potency against the
HIV-1 WT and the HIV-1 drug-resistant mutants. IASs
bearing the third nucleus linked at the carboxamide
nitrogen showed potent antiretroviral activity. Chiral
derivatives having (R) configuration were significantly
more potent than (S) counterparts against the HIV-1
mutant strains. The alanine spacer between the
carboxamide nitrogen and the a-methylbenzyl brought
attention to a correlation between configuration of
the asymmetric centre and linker length: the
(R)-enantiomers were superior to the (S)-counterparts
when associated to a short linker unit, and the
(S)-enantiomers were more potent than the (R)-enan-
tiomers in the presence of a long linker. IAS derivatives
are promising drug candidates for the treatment of
AIDS/HIV-1 infection in combination with other
HIV-1 agents. This review provides some key SARs
for the design and synthesis of new potent HIV-1
NNRTIs.
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